Visiongain has published a new report on Antiviral Drugs Treatment Market Report 2021-2031: Forecasts by Drug Class (Reverse Transcriptase Inhibitors, Protease Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Others), by Application (Hepatitis, HIV, Influenza, Herpes, Others), by End-user (Hospitals, Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Antiviral Drugs Companies AND COVID-19 Recovery Scenarios.

Global antiviral drugs treatment market was valued at US$ US$xx bn in 2020 and is projected to reach at a market value of US$xx billion by 2031. Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

COVID-19 Impact on Antiviral Drugs Treatment Market
The COVID-19 pandemic has a mixed impact on the antiviral drugs treatment market worldwide. The COVID-19 pandemic has resulted in the increasing prevalence of viral infection worldwide. Antiviral drugs are in high demand due to the ongoing Covid-19 pandemic. However, due to the breakdown of the value chain in relevant APIs exported from China, there is a global shortage being observed. However, the pharmaceutical and biologics companies are facing challenges while drug manufacturing and marketing due to the COVID-19 pandemic. With manufacturers working hard to continue positive credit, it is to be witnessed how antiviral drugs demand will be met.

Thus, the demand for these drugs impacted negatively since 2020. However, the market is expected to lucrative rate after 2021-2023 owing to the launch of the COVID-19 vaccine and growing viral infection awareness programs worldwide.

Market Drivers
Growing prevalence of rising prevalence of viral infection including HIV, influenza, herpes, hepatitis and other viral infections, increasing geriatric population; advancement in anti-viral drugs r&d; rising strategic initiatives for anti-viral drugs market and developing healthcare infrastructure in emerging economies are the major drivers boosting the global antiviral drugs treatment market.

Prevention, control, and management of viral diseases must be given significant importance in the health sector as viral diseases present challenges to the health of society members. For preventing viral diseases, environmental control and public awareness are important steps. The research and development activities in the field of viral diseases offer promising scenarios for anti-viral drugs. Due to extensive R&D, many cost-effective anti-viral drugs are available in the market.

For instance, in February 2021, Gilead Sciences, Inc. and Gritstone Oncology, announced that the companies have entered into a collaboration, option, and license agreement to research and develop vaccine-based immunotherapy as part of Gilead’s efforts to find a treatment for HIV infection.

Market Opportunities
The pharmaceutical industry is expected to witness growing demand for anti-viral drugs due to the COVID-19 pandemic. Therefore, the manufacturing companies are focusing on finding innovative ways to develop and manufacture anti-viral drugs for the treatment of COVID-19 infection. In outbreak conditions, treatment of MERS (Middle East respiratory syndrome) has concentrated on therapeutics with broad antiviral activity and good safety profiles, rather than efficacy evidence generated by cellular, nonhuman, or rodent primate models of contagious viral coronavirus disease. Based on the lessons learned from the MERS and SARS outbreaks, the shortage of drugs with pan-coronavirus antiviral activity makes public health systems more vulnerable to a pathogenic coronavirus disease outbreak.

A number of patent expiries are projected during the forecast period of the report, such as Sustiva, Combivir, Tamiflu, Tenofovir, Telbivudine, and Relenza. The report expects the patent expiries of these blockbuster drugs will initiate the development of generic therapeutics in the global antivirals market and make it more competitive. Pipeline drugs such as Elvitegravir, Rilpivirine, Vicriviroc, and Rapiacta are likely to positively influence the market upon arrival.

Competitive Landscape
Antiviral drugs treatment market is a highly competitive market with several global and local players. Some of the major players operating in the market are AbbVie, Cipla, Gilead Sciences, GlaxoSmithKline (GSK), Novartis, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim Corporation, AstraZeneca AB, Johnson & Johnson, Merck & Co, Bristol-Myers-Squibb and Abbott Laboratories.

All above mentioned market player have adopted various strategies comprising M&A, R&D investment, collaborations, regional expansion, and new product launches. For instance, in Mar. 2021 Cipla Limited announced that its subsidiary, Cipla Gulf FZ LCC (“Cipla Gulf’) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

In Feb. 2021, Gilead Sciences, Inc. and Gritstone Oncology, announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.